172 related articles for article (PubMed ID: 24152044)
1. Overcoming melanoma drug resistance through metabolic targeting?
Smalley KS
Pigment Cell Melanoma Res; 2013 Nov; 26(6):793-5. PubMed ID: 24152044
[No Abstract] [Full Text] [Related]
2. Hepatocyte growth factor in the neighborhood reverses resistance to BRAF inhibitor in melanoma.
Nickoloff BJ; Vande Woude G
Pigment Cell Melanoma Res; 2012 Nov; 25(6):758-61. PubMed ID: 22974232
[No Abstract] [Full Text] [Related]
3. Nivolumab success in untreated metastatic melanoma.
Wilkinson E
Lancet Oncol; 2015 Jan; 16(1):e9. PubMed ID: 25638562
[No Abstract] [Full Text] [Related]
4. Metabolic features of melanoma: a gold mine of new therapeutic targets?
Marchetti P; Guerreschi P; Kluza J; Mortier L
Curr Cancer Drug Targets; 2014; 14(4):357-70. PubMed ID: 24720363
[TBL] [Abstract][Full Text] [Related]
5. The new arms race against melanoma.
Lejeune FJ
Melanoma Res; 2006 Feb; 16(1):1-2. PubMed ID: 16432449
[No Abstract] [Full Text] [Related]
6. Chemotherapy for melanoma: the resultant of conflicting vectors.
Mitchell MS
J Clin Oncol; 2004 Jun; 22(11):2043-5. PubMed ID: 15123732
[No Abstract] [Full Text] [Related]
7. Bench to bedside: mechanistic principles of targeting the RAF kinase in melanoma.
Rajakulendran T; Adam DN
Int J Dermatol; 2014 Dec; 53(12):1428-33. PubMed ID: 25311997
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo anti-melanoma effects of ciglitazone.
Botton T; Puissant A; Bahadoran P; Annicotte JS; Fajas L; Ortonne JP; Gozzerino G; Zamoum T; Tartare-Deckert S; Bertolotto C; Ballotti R; Rocchi S
J Invest Dermatol; 2009 May; 129(5):1208-18. PubMed ID: 19177142
[TBL] [Abstract][Full Text] [Related]
9. New drug targets in metastatic melanoma.
Homet B; Ribas A
J Pathol; 2014 Jan; 232(2):134-41. PubMed ID: 24027077
[TBL] [Abstract][Full Text] [Related]
10. Editorial: melanomas and Wnts.
Goding C
Pigment Cell Res; 2005 Jun; 18(3):149. PubMed ID: 15892710
[No Abstract] [Full Text] [Related]
11. Is there a role for targeting vascular endothelial growth factor/receptor axis in the treatment of patients with metastatic melanoma?
Kim KB
Cancer; 2013 Feb; 119(3):477-80. PubMed ID: 22915026
[No Abstract] [Full Text] [Related]
12. Reactive oxygen species may have antitumor activity in metastatic melanoma.
Tuma RS
J Natl Cancer Inst; 2008 Jan; 100(1):11-2. PubMed ID: 18159075
[No Abstract] [Full Text] [Related]
13. TGF-β may control the switch between tumorigenic growth and "stem cell/mesenchymal" potentially drug-resistant states.
Bordelon JR; Grichnik JM
Dermatol Ther; 2015; 28(3):177-8. PubMed ID: 25649199
[No Abstract] [Full Text] [Related]
14. [Melanoma and search for therapeutic targets].
de la Fouchardière A
Ann Pathol; 2011 Nov; 31(5 Suppl):S123-4. PubMed ID: 22054449
[No Abstract] [Full Text] [Related]
15. Unveil the mysterious mask of cytokine-based immunotherapy for melanoma.
Xu DH; Zhu Z; Xiao H; Wakefield MR; Bai Q; Nicholl MB; Ding VA; Fang Y
Cancer Lett; 2017 May; 394():43-51. PubMed ID: 28254411
[TBL] [Abstract][Full Text] [Related]
16. Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets.
Grossman D; Altieri DC
Cancer Metastasis Rev; 2001; 20(1-2):3-11. PubMed ID: 11831644
[TBL] [Abstract][Full Text] [Related]
17. Neurotrophin Receptors and Perineural Invasion: Analyses in Select Lineage-Unrelated Cutaneous Malignancies With a Propensity for Perineural Invasion.
Frydenlund NF; Mahalingam M
Vitam Horm; 2017; 104():497-531. PubMed ID: 28215306
[TBL] [Abstract][Full Text] [Related]
18. Targeting invasive properties of melanoma cells.
Arozarena I; Wellbrock C
FEBS J; 2017 Jul; 284(14):2148-2162. PubMed ID: 28196297
[TBL] [Abstract][Full Text] [Related]
19. 3,3',4,4',5,5'-hexahydroxystilbene impairs melanoma progression in a metastatic mouse model.
Paulitschke V; Schicher N; Szekeres T; Jäger W; Elbling L; Riemer AB; Scheiner O; Trimurtulu G; Venkateswarlu S; Mikula M; Swoboda A; Fiebiger E; Gerner C; Pehamberger H; Kunstfeld R
J Invest Dermatol; 2010 Jun; 130(6):1668-79. PubMed ID: 19956188
[TBL] [Abstract][Full Text] [Related]
20. Targeting x-linked inhibitor of apoptosis protein for melanoma therapy: the need for more homogeneous samples and the importance of cell lines.
Kwatra SG
J Invest Dermatol; 2011 Mar; 131(3):797. PubMed ID: 21068753
[No Abstract] [Full Text] [Related]
[Next] [New Search]
